These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20371755)

  • 1. Association of pancreatitis with glucagon-like peptide-1 agonist use.
    Anderson SL; Trujillo JM
    Ann Pharmacother; 2010 May; 44(5):904-9. PubMed ID: 20371755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatitis: a potential complication of liraglutide?
    Franks AS; Lee PH; George CM
    Ann Pharmacother; 2012 Nov; 46(11):1547-53. PubMed ID: 23136352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
    Alves C; Batel-Marques F; Macedo AF
    Diabetes Res Clin Pract; 2012 Nov; 98(2):271-84. PubMed ID: 23010561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of vildagliptin in the management of type 2 diabetes mellitus.
    Kleppinger EL; Helms K
    Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute pancreatitis associated with liraglutide.
    Lee PH; Stockton MD; Franks AS
    Ann Pharmacother; 2011 Apr; 45(4):e22. PubMed ID: 21487080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
    Gallwitz B
    Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M; Rayfield EJ
    Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide for the treatment of type 2 diabetes mellitus.
    Ruddock B
    Issues Emerg Health Technol; 2005 Aug; (71):1-4. PubMed ID: 16389694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-drug interactions with glucagon-like peptide-1 receptor agonists.
    Hurren KM; Pinelli NR
    Ann Pharmacother; 2012 May; 46(5):710-7. PubMed ID: 22510669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 13. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients.
    Pinelli NR; Jones MC; Monday LM; Smith Z; Rhoney DH
    Ann Pharmacother; 2012 Jan; 46(1):124-9. PubMed ID: 22202493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
    Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
    Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide. Amylin/Eli Lilly.
    Giannoukakis N
    Curr Opin Investig Drugs; 2003 Apr; 4(4):459-65. PubMed ID: 12808888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
    Chalmer T; Almdal TP; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.